Overview

Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM

Status:
Completed
Trial end date:
2019-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to determine whether treatment with valsartan will have beneficial effect in early hypertrophic cardiomyopathy (HCM) by assessing many domains that reflect myocardial structure, function and biochemistry.
Phase:
Phase 2
Details
Lead Sponsor:
HealthCore-NERI
New England Research Institutes
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Treatments:
Valsartan